DENIS DEVENPORT: Open Payments
NPI 1588724124 · LA PLACE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,970 in 99 payments from 12 companies in 2025. Trend: 2023 $954 · 2024 $1,435 · 2025 $1,970
Food & beverage: $1,968Education: $1
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 18 | $347 |
| Neurocrine BioSciences, Inc. | 9 | $242 |
| Alkermes, Inc. | 12 | $234 |
| ABBVIE INC. | 14 | $210 |
| E.R. Squibb & Sons, L.L.C. | 12 | $190 |
| Vanda Pharmaceuticals Inc. | 10 | $176 |
| Supernus Pharmaceuticals, Inc. | 5 | $173 |
| Janssen Pharmaceuticals, Inc | 5 | $127 |
| Axsome Therapeutics, Inc. | 6 | $122 |
| Teva Pharmaceuticals USA, Inc. | 5 | $92 |
Products named: INGREZZA, ARISTADA, VRAYLAR, REXULTI, COBENFY, FANAPT, Qelbree, Auvelity.
Industry payments across LA — which companies pay providers there.
